Bafna Pharmaceuticals Limited - Asset Resilience Ratio
Bafna Pharmaceuticals Limited (BAFNAPH) has an Asset Resilience Ratio of 1.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Bafna Pharmaceuticals Limited PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Bafna Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. See BAFNAPH net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bafna Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bafna Pharmaceuticals Limited (BAFNAPH) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs17.13 Million | 1.07% |
| Total Liquid Assets | Rs17.13 Million | 1.07% |
Asset Resilience Insights
- Limited Liquidity: Bafna Pharmaceuticals Limited maintains only 1.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bafna Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Bafna Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Bafna Pharmaceuticals Limited (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Bafna Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 0.47% | Rs6.99 Million ≈ $75.63K |
Rs1.48 Billion ≈ $15.97 Million |
-0.75pp |
| 2021-03-31 | 1.22% | Rs10.56 Million ≈ $114.21K |
Rs864.66 Million ≈ $9.35 Million |
-0.93pp |
| 2019-03-31 | 2.15% | Rs25.74 Million ≈ $278.34K |
Rs1.19 Billion ≈ $12.92 Million |
+0.38pp |
| 2018-03-31 | 1.77% | Rs24.50 Million ≈ $264.97K |
Rs1.38 Billion ≈ $14.96 Million |
-- |
About Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more